Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Conditions

• Non-small Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• SBRT — RADIATION
  Please refer to the current NCCN NSCLC guidelines for possible treatment options
• First or second-line standard of care therapy — OTHER
  Please refer to the current NCCN NSCLC guidelines for possible treatment options.

Study Details

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.

Key Dates

Start date

Dec 16, 2025

Status verified

Mar 2026

Primary completion

Feb 28, 2030

Completion

Dec 31, 2030

Study Design

Enrollment

320 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: SBRT/Radiotherapy followed by standard of care therapy
• Active Comparator: Systemic therapy at the investigator's discretion, no SBRT

Primary Outcome Measure

Progression-free survival [ Time Frame: 5.5 years ]

Central Contacts

• Pierre-Olivier Gaudreau
  613-533-6430
  [email protected]

Locations (70)

Find similar trials in Phoenix, AZ

Related Studies

• Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
  PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
• JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
  PHASE3 · Recruiting · University of Texas Southwestern Medical Center · La Jolla, California
• Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
  Recruiting · University of Missouri-Columbia · Columbia, Missouri
• Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
  Recruiting · University of Colorado, Denver · Aurora, Colorado